Valuation: BioRestorative Therapies, Inc.

Market Cap 7.39M 6.49M 6.04M 5.54M 10.41M 712M 10.57M 71.66M 28M 350M 27.74M 27.14M 1.21B P/E 2026 *
-0.59x
P/E 2027 * -0.72x
Enterprise Value 7.39M 6.49M 6.04M 5.54M 10.41M 712M 10.57M 71.66M 28M 350M 27.74M 27.14M 1.21B EV / Sales 2026 *
5.26x
EV / Sales 2027 * 3.2x
Free-Float
87.87%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 55 15/11/2020
Director of Finance/CFO 59 03/11/2021
Investor Relations Contact - -
Director TitleAgeSince
Chairman 55 15/11/2020
Director/Board Member 61 28/10/2021
Director/Board Member 28 11/06/2026
Change 5-day change 1-year change 3-year change Capi.($)
+1.08%+0.25% - - 7.39M
-1.39%+5.31%+55.06%+69.18% 57.28B
-1.92%+6.03%+40.64%+80.66% 54.99B
-0.18%-0.32%+4.84%+422.92% 23.18B
+2.51%-0.62%-18.80%-12.77% 22.59B
-1.13%+1.05%+20.81%-7.73% 20.46B
+1.05%+2.95%+26.98%-29.31% 17.56B
-0.10%+1.88%+34.42%+545.91% 15.67B
-1.30%-5.02%+170.77%+310.94% 14.46B
+1.65%+1.66%+27.17%+188.01% 13.92B
Average +0.01%+1.28%+40.21%+174.20% 26.68B
Weighted average by Cap. -0.56%+2.10%+39.00%+137.04%

Financials

2026 *2027 *
Net sales 1.4M 1.23M 1.15M 1.05M 1.98M 135M 2.01M 13.63M 5.32M 66.52M 5.27M 5.16M 230M 2.31M 2.03M 1.89M 1.73M 3.26M 223M 3.31M 22.43M 8.76M 109M 8.68M 8.49M 379M
Net income -13.52M -11.88M -11.05M -10.14M -19.05M -1.3B -19.34M -131M -51.25M -640M -50.77M -49.67M -2.21B -15.56M -13.67M -12.71M -11.66M -21.91M -1.5B -22.25M -151M -58.96M -737M -58.41M -57.15M -2.55B
Net Debt - -
Logo BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-